Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kocabaş Umut, Ergin Işıl, Yavuz Veysel, Murat Selda, Özdemir Ibrahim, Genç Ömer, Altın Cihan, Tüner Haşim, Keskin Meriç Bengisu, Çoner Ali, İlkay Yüce Elif, Boyraz Bedrettin, Aslan Onur, Dal Ahmet, Şen Taner, İbişoğlu Ersin, Erdoğan Aslan, Özgeyik Mehmet, Demir Mevlüt, Bilgel Ziya Gökalp, Güvendi Şengör Büşra, Urgun Örsan Deniz, Doğduş Mustafa, Naki Tekin Deniz Dilan, Çakal Sinem, Çayırlı Sercan, Güler Arda, Karabulut Dilay, Dalgıç Onur, Uzman Osman, Murat Bektaş, Şahin Şeyda, Karabulut Umut, Kıvrak Tarık, Coşgun Muharrem Said, Özyurtlu Ferhat, Kaplan Mehmet, Özçalık Emre
Аннотация
METHODS: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021.
RESULTS: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2-VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants.
CONCLUSIONS: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation.time in therapeutic range with <70%.